Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

Cerimon initiates enrollment into phase III clinical studies of diclofenac sodium patch

Feb. 26, 2009

Winston receives orphan drug designation for novel postherpetic neuralgia patch

Feb. 26, 2009

Valdoxan approved for the treatment of major depressive episodes in Europe

Feb. 26, 2009

Insulin signaling, a potential target for Alzheimer's disease

Feb. 26, 2009

New norepinephrine, 5-HT and dopamine reuptake inhibitors in development at DOV

Feb. 26, 2009

NeuroSearch reports phase II proof-of-concept results for NS-2359 in depression

Feb. 25, 2009

Ambrx and Merck Serono sign agreement to develop and commercialize ARX-424 for MS

Feb. 25, 2009

Primary objective of STRIDE-PD Stalevo study was not achieved

Feb. 25, 2009

GW reports encouraging results in randomized withdrawal Sativex study

Feb. 25, 2009

New Nav1.7 sodium channel blockers presented by AstraZeneca

Feb. 25, 2009

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 6, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 3, 2026
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
Muscarinic M4 receptor positive allosteric modulators described in Neurosterix patent
BioWorld Science
Neurosterix Pharma Sarl has divulged 3-cyclopropylpyrazole derivatives acting as muscarinic M4 receptor positive allosteric modulators. They are reported to be...